Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib in Previously-Treated Malignant Mesothelioma
NCT01861301Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivantinib in malignant mesothelioma, sponsored by National Cancer Institute. Primary endpoint: Objective Radiologic Response Rate at 1 year. Started Jan 2013; status: terminated.
02
Drugs
tivantinib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT01861301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861301.